TNFRSF1A and respiratory syncytial virus bronchiolitis: Our main findings demonstrate that mice which received an optimal dose of 80 μg of anti-TNFR1 Ab prior to viral inoculation showed significant improvements in clinical disease and airway bronchconstriction, a hallmark of RSV bronchiolitis in infants [33,34].